Patcharee KanjanawatDayin KoompalumSummana MoolasarnAnoree Surawong2011-02-202011-02-202009-12-222009-12-22Isan Journal of Pharmaceutical Sciences - วารสารเภสัชศาสตร์อีสาน; Volume 5 No.2 May-August 2009; 140-148http://imsear.searo.who.int/handle/123456789/130702The objective of this study was to determine direct medical costs and treatment outcomes of acute leukemia patients: Acute lymphoblastic leukemia (ALL), acute Myeloid leukemia (AML) and acute promyelocytic leukemia (APL), in Sappasittiprasong hospital. The study was a retrospective descriptive of newly diagnosed acute leukemia patients admitted at Sappasittiprasong hospital was carried out from October 1, 2004 to September 30, 2006. The treatment outcomes data collected for 2 years of treatment and the cost data collected for 1 year of treatment by using a health care providers perspective. As a result, 151 acute leukemia patients were enrolled; 45 were children, all received chemotherapy; 106 were adult. 2-years Survival rates of child patients with ALL, AML, and APL were 68.57%, 37.50% and 100%. In adult patients, who received chemotherapy were 6.25%, 4.69% and 25%, median survival time were 3.50, 2.87 and 14.47 months, respectively. Median survival time in adult AML patients receiving palliative chemotherapy and no chemotherapy were 0.57 and 1.03 months, respectively. The first-year of median direct medical costs for child with ALL, AML, APL were 166,544, 366,147 and 360,647 baht, and for adult patients, who received chemotherapy were 115,911, 349,658, and 169,904 baht, respectively. In conclusion, the costs and treatment outcomes of patients with acute leukemia in Sappasittiprasong hospital were varied by types of acute leukemia, treatment protocols and chemotherapy regimens. Thus, to increase patient survival rates, more studies should be conducted to determine factors associated with costs and treatment outcomes.en-USIsan Journal of Pharmaceutical Sciences - วารสารเภสัชศาสตร์อีสานOriginal Articles